This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Biocept Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Antonino Morales

Directeur général

US$781.6k

Rémunération totale

Pourcentage du salaire du PDG	46.8%
Durée du mandat du directeur général	less than a year
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	3.7yrs
Durée moyenne du mandat des membres du conseil d'administration	5.9yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Antonino Morales a-t-elle évolué par rapport aux bénéfices de Biocept?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$782k	US$366k	-US$32m
Sep 30 2022	n/a	n/a	-US$25m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$57k	n/a	-US$3m

Rémunération vs marché: La rémunération totale de Antonino ($USD 781.63K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 474.54K ).

Rémunération et revenus: La rémunération de Antonino a augmenté alors que l'entreprise n'est pas rentable.

PDG

Antonino Morales (67 yo)

less than a year

Titularisation

US$781,631

Compensation

Mr. Antonino Morales serves as Director of Biocept, Inc., since July 20, 2021 and served as its Interim Chief Financial Officer since February 15, 2022 until June 21, 2023 and serves as its Chief Executive...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Antonino Morales	CEO, President & Director	less than a year	US$781.63k	pas de données
Darrell Taylor	Chief Legal Officer	1.5yrs	US$773.28k	0% € 0
Soon Hahn	Founder	26.6yrs	pas de données	pas de données
Rob Walsh	VP & Controller	less than a year	pas de données	pas de données
Philippe Marchand	Chief Operating Officer	1.4yrs	pas de données	pas de données
Pavel Tsinberg	Director of Technology Development	5.9yrs	pas de données	pas de données
David Moskowitz	Vice President of Strategy & Corporate Communications	6.8yrs	pas de données	pas de données
Veena Singh	Senior Medical Director	8.7yrs	US$441.87k	pas de données

3.7yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Gestion expérimentée: L'équipe de direction de B00 est considérée comme expérimentée (ancienneté moyenne 3.7 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Antonino Morales	CEO, President & Director	2.1yrs	US$781.63k	pas de données
Ivor Royston	Independent Director	13.6yrs	US$65.21k	0.00014% € 2.1
Linda Rubinstein	Independent Director	2.1yrs	US$57.26k	0% € 0
Quyen Dao-Haddock	Independent Director	less than a year	US$13.32k	0% € 0
Marsha Chandler	Independent Vice Chairman of the Board	9.8yrs	US$70.21k	0.000070% € 1.0
Fred Hirsch	Member of Clinical Advisory Board	no data	pas de données	pas de données
Bruce Gerhardt	Independent Chairman of the Board	12.8yrs	US$67.71k	0.0010% € 15.1

5.9yrs

Durée moyenne de l'emploi

72yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de B00 sont considérés comme expérimentés (ancienneté moyenne 5.9 ans).

This company is no longer active

Biocept Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Biocept, Inc. Announces Executive Changes

Biocept, Inc. Appoints Quyen Dao-Haddock to the Board of Directors

Biocept, Inc., Annual General Meeting, Jun 10, 2022

Biocept, Inc. Appoints Philippe Marchand as Chief Operating Officer

Biocept, Inc. Announces Management Changes

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

Recent updates

Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index

Biocept's Securities To Be Delisted from Nasdaq

Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index

Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer

Biocept, Inc. Announces Executive Changes

Biocept Expects to Receive Non-Compliance Notice Form Nasdaq

No longer forecast to breakeven

Full year 2022 earnings released: US$1.89 loss per share (vs US$0.19 loss in FY 2021)

No longer forecast to breakeven

Forecast to breakeven in 2025

Biocept, Inc. Appoints Quyen Dao-Haddock to the Board of Directors

Biocept, Inc. announced delayed 10-Q filing

Biocept Receives Non-Compliance Letter from Nasdaq

Biocept, Inc. Expands Commercial Offering of Cnside(Tm) Assay to Most Cancers That Metastasize to the Central Nervous System

Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc., Annual General Meeting, Jun 10, 2022

Biocept, Inc. announced delayed annual 10-K filing

Investor sentiment improved over the past week

Biocept, Inc. Appoints Philippe Marchand as Chief Operating Officer

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Biocept, Inc. Announces Management Changes

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain

Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season

Third quarter 2021 earnings released: EPS US$0.056 (vs US$0.43 loss in 3Q 2020)

Biocept, Inc. Implements Covid-19 Testing Program at Select California Community Colleges

Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations

Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.51 loss in 2Q 2020)

Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

First quarter 2021 earnings released: EPS US$0.19 (vs US$1.06 loss in 1Q 2020)

Full year 2020 earnings released: US$1.50 loss per share (vs US$12.23 loss in FY 2019)

Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load

Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients

New 90-day high: €6.05

New 90-day high: €5.10

Biocept, Inc. Enters into Laboratory Services Agreements with Independent Physician Associations

Biocept, Inc. Announces to Receives More Than 150,000 Samples for Covid-19 RT-PCR Testing

Biocept, Inc.'s Target Selector™ Liquid Biopsy Demonstrate High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center

New 90-day high: €4.80

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations

Biocept, Inc. Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, Including Cancer Cells

Biocept, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Biocept, Inc. Provides Update on COVID-19 Testing with More than 50,000 Specimens Received

New 90-day low: €3.62

Biocept, Inc. Announces That Highmark Has Made A Positive Coverage Determination on Target Selector Liquid Biopsy

New 90-day low: €3.69

Biocept, Inc. Provides COVID-19 Testing Update with More Than 21,000 COVID-19 Specimens Received and More Than 20,000 Specimens Processed

New 90-day low: €3.69

New 90-day low - €3.69

New 90-day low - €0.37

Biocept, Inc. Announces One-For-Ten Reverse Stock Split to Regain Compliance

First half earnings released

New 90-day high - €0.92

Biocept, Inc. to Report Q2, 2020 Results on Aug 12, 2020

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen